CG Oncology (NASDAQ:CGON) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of CG Oncology (NASDAQ:CGON) in a research note issued to investors on Thursday, Benzinga reports. Cantor Fitzgerald currently has a $75.00 price target on the stock.

CGON has been the subject of a number of other reports. The Goldman Sachs Group began coverage on shares of CG Oncology in a research report on Tuesday, February 20th. They set a neutral rating and a $42.00 price target for the company. HC Wainwright reiterated a buy rating and issued a $75.00 target price on shares of CG Oncology in a report on Thursday, April 4th. Finally, Morgan Stanley began coverage on CG Oncology in a research note on Tuesday, February 20th. They set an overweight rating and a $55.00 price target on the stock.

CG Oncology Price Performance

NASDAQ CGON opened at $36.27 on Thursday. The business’s fifty day simple moving average is $39.63. CG Oncology has a twelve month low of $28.55 and a twelve month high of $50.23.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in CG Oncology stock. BNP Paribas Financial Markets purchased a new stake in CG Oncology, Inc. (NASDAQ:CGON) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 11,198 shares of the company’s stock, valued at approximately $492,000. Institutional investors own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.